Global arthritis therapeutics market led by Pfizer, Roche and Novartis

Press Release   •   Feb 14, 2013 12:07 GMT

The global arthritis therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 7.2% over the next five years, with the industry rising from a valuation of $20.6 billion in 2010, to hit a market value of $38 billion by 2018.

Rheumatoid arthritis is a chronic inflammatory disease that leads to pain, stiffness, swelling and limitation in the motion and function of multiple joints. If left untreated, rheumatoid arthritis can produce serious destruction of joints that frequently leads to permanent disability.

The market share of rheumatoid arthritis, osteoarthritis, psoriatic arthritis and ankylosing spondylitis in the overall arthritis market was 68%, 22%, 7.4% and 2.6%, respectively, in 2010.

The rheumatoid arthritis market was valued at $14 billion in 2010, with market revenue expected to increase to $26.9 billion by 2018, at a CAGR of 8.5%. The osteoarthritis market is expected to show slower growth among the top four indications.

The rich arthritis pipeline is likely to support the growth of this market thereby attracting many pharmaceutical and biotechnological companies.

Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche and Novartis are already active in R&D for arthritis therapies.

The top six companies in the arthritis therapeutics market accounted for a share of close to 62% in 2010, leaving 38% of the market dominated by generic therapies and smaller players. Despite a significant number of products available on the market, the high value of biologics keeps the market value high.

For more information on the global arthritis therapeutics market, see the latest research: Global Arthritis Therapeutics Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.